Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea and application of lactobacillus rhamnosus composition

Abstract

The invention discloses a lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea and application of the lactobacillus rhamnosus composition, the composition is composed of a probiotic mixture, a prebiotic mixture and a carrier, the probiotic mixture is composed of lactobacillus plantarum JY055 bacterial powder, lactobacillus rhamnosus JM039 bacterial powder and lactobacillus rhamnosus JY027 bacterial powder, and the prebiotic mixture is composed of lactobacillus plantarum JY055 bacterial powder, lactobacillus rhamnosus JM039 bacterial powder and lactobacillus rhamnosus JY027 bacterial powder. The prebiotic mixture comprises inulin, xylitol, lactulose, resistant dextrin, a hawthorn extract and a dandelion extract, and the carrier is modified montmorillonite. The composition for relieving gastrointestinal diarrhea provided by the invention is composed of a mixture of three probiotics and prebiotics, and the probiotics are adhered to small intestinal mucosa epithelial cells to form a mycoderm and form an intestinal barrier, so that colonization and growth of harmful bacteria are prevented, self-protection of intestinal epithelial cells is enhanced, and the damaged intestinal barrier is repaired; the prebiotic mixture provides a breeding place and nutrient elements for growth and breeding of the probiotics, and the efficacy can be improved through mutual cooperation of the prebiotic mixture and the probiotics.

Description

Technical Field

[0001] The invention relates to the technical field of medicines, and in particular to a Lactobacillus rhamnosus composition for alleviating gastrointestinal diarrhea and an application thereof. Background Art

[0002] There are a large number of microorganisms with various types and complex functions in the human intestine, and the number of their cells is more than 10 times that of human cells. Under normal conditions, the intestinal flora restrict and coordinate with each other to maintain a complex and stable intestinal microbial ecological balance; once this balance is broken, the intestinal flora is imbalanced, the number of probiotics decreases, the number of pathogenic bacteria increases, and various diseases related to intestinal flora follow. Diarrhea is a common intestinal disease, and its main clinical manifestations are increased bowel movements, 3 or more bowel movements per day, and abnormal stool characteristics, such as loose stools and watery stools.

[0003] The gastrointestinal system mainly absorbs and excretes fluids and nutrients. Its operating mechanism is complex. Under the influence of certain factors, the intestinal microecological system is destroyed, resulting in abnormal changes in the types, quantity and proportion of normal intestinal flora, and pathological combination states, which cause diarrhea. Acute diarrhea remains a global public health problem, especially in developing countries, and is an important cause of morbidity and mortality among children. The most common cause of diarrhea is infection with different microorganisms, and its most common complication is dehydration.

[0004] At present, diarrhea is mainly treated with antibiotics. However, the frequent use of large amounts of antibiotics can cause Escherichia coli to develop drug resistance and destroy the normal intestinal flora. The residues of antibiotics also pose a great threat to daily production and life. Therefore, there is an urgent need for a drug that can relieve diarrhea without destroying the balance of intestinal flora to replace antibiotics. Summary of the invention

[0005] The main purpose of the present invention is to provide a Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea and its application, aiming to solve the problem that the existing antibiotics for treating diarrhea destroy the normal flora in the intestine.

[0006] To achieve the above object, the present invention proposes a Lactobacillus rhamnosus composition for alleviating gastrointestinal diarrhea, the composition consisting of a probiotic mixture, a prebiotic mixture and a carrier, the probiotic mixture consisting of Lactobacillus plantarum JY055 powder, Lactobacillus rhamnosus JM039 powder and Lactobacillus rhamnosus JY027 powder, the prebiotic mixture comprising inulin, xylitol, lactulose, resistant dextrin, hawthorn extract and dandelion extract, and the carrier is modified montmorillonite.

[0007] The plant lactobacillus JY055 provided by the present invention can produce extracellular polysaccharides, improve the intestinal adhesion ability of Lactobacillus rhamnosus JM039 and Lactobacillus rhamnosus JY027, Lactobacillus rhamnosus JM039 helps to inhibit intestinal inflammatory response, Lactobacillus rhamnosus JY027 can improve colon mucosal damage, and the three probiotics cooperate with each other to improve the balance of intestinal microorganisms; the modified montmorillonite provided by the present invention can be combined with mucus glycoprotein to enhance the defense function of the intestinal mucosal barrier, thereby facilitating the restoration of intestinal flora balance and inhibiting the body's inflammation level. The modified montmorillonite has good dispersibility and is suitable for plant lactobacillus JY055. It provides a breeding place for three probiotics, Lactobacillus plantarum JY055, Lactobacillus rhamnosus JM039 and Lactobacillus rhamnosus JY027, which is conducive to the colonization and growth of probiotics; dandelion extract has pharmacological effects such as anti-inflammatory, anti-harmful bacteria and antioxidant; hawthorn extract is rich in flavonoids, polyphenols and organic acids, which can promote the growth of Lactobacillus plantarum JY055, Lactobacillus rhamnosus JM039 and Lactobacillus rhamnosus JY027 in the intestine, inhibit the proliferation of harmful bacteria, and thus improve the balance of intestinal microecology; lactulose reaches the colon and is decomposed into lactic acid by bacteria, which stimulates intestinal peristalsis and has a laxative effect.

[0008] Optionally, the mass ratio of the probiotic mixture to the prebiotic mixture is (3-6):(4-8).

[0009] Optionally, the viable count of the Lactobacillus plantarum JY055 powder is ≥ 1.0×10 9 CFU / g, the viable count of the Lactobacillus rhamnosus JM039 powder is ≥1.0×10 8 CFU / g, the viable count of the Lactobacillus rhamnosus JY027 powder is ≥2.0×10 8 CFU / g.

[0010] Optionally, the mass ratio of Lactobacillus plantarum JY055 powder, Lactobacillus rhamnosus JM039 powder, and Lactobacillus rhamnosus JY027 powder in the probiotic mixture is (6-8):(4-5):(1-3).

[0011] Optionally, the preparation method of the modified montmorillonite comprises the following steps: NaCl solution is added to montmorillonite, stirred, centrifuged to remove the supernatant, washed with deionized water, dried, and crushed to obtain Na-based montmorillonite; chitosan is dissolved in acetic acid, added to the Na-based montmorillonite, stirred, centrifuged to remove the supernatant, washed with deionized water, dried, and crushed to obtain modified montmorillonite.

[0012] Optionally, the mass ratio of inulin, xylitol, lactulose, resistant dextrin, hawthorn extract, dandelion extract and modified montmorillonite is (1-2): (1-3): (2-5): (0.2-0.6): (6-10): (4-7), (0.2-0.4).

[0013] The present invention also proposes a method for preparing the Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea as described above, comprising the following steps: stirring and mixing inulin, xylitol, lactulose, resistant dextrin, hawthorn extract, dandelion extract and modified montmorillonite in proportion, sterilizing at 110-130° C., then adding Lactobacillus plantarum JY055 powder, Lactobacillus rhamnosus JM039 powder and Lactobacillus rhamnosus JY027 powder, and mixing evenly to obtain the Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea.

[0014] The present invention also provides the use of the above-mentioned composition in preparing a drug for alleviating diarrhea.

[0015] Compared with the prior art, the beneficial effects of the present invention are: (1) The Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea provided by the present invention is composed of three probiotics and a prebiotic mixture. The probiotics adhere to the small intestinal mucosal epithelial cells to form a biofilm, which constitutes an intestinal barrier, prevents the colonization and growth of harmful bacteria, enhances the self-protection of intestinal epithelial cells and repairs the damaged intestinal barrier; and the prebiotic mixture provides a breeding place and nutrients for the growth and proliferation of probiotics. The two work together to improve the efficacy of the drug. The composition provided by the present invention can effectively regulate the balance of intestinal microorganisms and relieve diarrhea through the reasonable combination and interaction of the components in the probiotic mixture and the prebiotic mixture. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0017] Figure 1 It is a stool trait scoring diagram of Examples 1 to 3 of the present invention and Comparative Examples 1 to 5.

[0018] The realization of the purpose, functional features and advantages of the present invention will be further explained in conjunction with embodiments and with reference to the accompanying drawings. DETAILED DESCRIPTION

[0019] To make the purpose, technical scheme and advantages of the embodiment of the present invention clearer, the technical scheme in the embodiment of the present invention will be clearly and completely described below. If the specific conditions are not specified in the embodiment, it is carried out according to the normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified in the reagents or instruments used, they are all conventional products that can be purchased commercially. In addition, the technical schemes between the various embodiments can be combined with each other, but must be based on the ability of ordinary technicians in the field to achieve. When the combination of technical solutions is contradictory or cannot be achieved, it should be considered that the combination of such technical solutions does not exist, and is not within the scope of protection required by the present invention. Based on the embodiments in the present invention, all other embodiments obtained by ordinary technicians in the field without making creative work belong to the scope of protection of the present invention.

[0020] The technical solution of the present invention is further described in detail below in conjunction with specific embodiments and drawings. It should be understood that the following embodiments are only used to explain the present invention and are not used to limit the present invention.

[0021] Lactobacillus plantarum JY055 is deposited in the Guangdong Microbiological Culture Collection Center, and the deposit address is the Institute of Microbiology, Guangdong Academy of Sciences, 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou. The deposit date is August 27, 2022, and the deposit number is GDMCC.No62720. Lactobacillus rhamnosus JM039 is deposited in the Guangdong Microbiological Culture Collection Center, and the deposit date is March 11, 2024, and the deposit number is GDMCC NO: 64409. Lactobacillus rhamnosus JY027 (Lacticaseibacillusrhamnosus) is deposited in the Guangdong Microbiological Culture Collection Center, and the deposit date is November 21, 2022, and the deposit number is GDMCC NO: 62991. Hawthorn extract was purchased from Xi'an Minglang Biotechnology Co., Ltd.; dandelion extract was purchased from Xi'an Jinheng Chemical Co., Ltd.

[0022] Preparation of bacterial powder (1) Preparation of Lactobacillus plantarum JY055 powder Inoculate Lactobacillus plantarum JY055 into MRS liquid culture medium at a 4% inoculum amount and activate it at 37°C for 16 hours. Use an inoculation loop to take a small amount of bacterial liquid and make three-zone lines on MRS solid culture medium. Culture it at 37°C for 48 hours, pick a single colony to the fermentation medium, and culture it at 37°C for 16 hours to obtain the bacteria. Centrifuge the bacteria, add it to a freeze-drying protective solution containing 10% skim milk powder, 0.8% glutamic acid and 1% vitamin E, mix and freeze-dry to obtain Lactobacillus plantarum JY055 powder. The content of Lactobacillus plantarum JY055 in the powder is 1.2×10 9 cfu / g.

[0023] The MRS liquid culture medium includes, by mass fraction, 2.0% glucose, 0.2% ammonium citrate, 0.5% sodium acetate, 0.03% manganese sulfate, 0.05% magnesium sulfate, 1.0% peptone, 1.0% beef extract, 0.5% yeast extract, 0.2% Trent-80, and the balance water; pH 6.0-6.2.

[0024] The MRS solid culture medium includes, by mass fraction, 2.0% glucose, 0.2% ammonium citrate, 0.5% sodium acetate, 0.03% manganese sulfate, 0.05% magnesium sulfate, 1.0% peptone, 1.0% beef extract, 0.5% yeast extract, 1.5% agar powder, 0.2% soil temperature-80, and the balance water; pH 6.0-6.2.

[0025] (2) Preparation of Lactobacillus rhamnosus JM039 powder Inoculate Lactobacillus rhamnosus JM039 into MRS liquid culture medium at a 4% inoculation rate and activate at 37°C for 16 hours. Use an inoculation loop to take a small amount of bacterial liquid and make three-zone lines on MRS solid culture medium. Culture at 37°C for 48 hours, pick a single colony to the fermentation medium, and culture at 37°C for 16 hours to obtain the bacteria. Centrifuge the bacteria, add it to a freeze-drying protective solution containing 10% skim milk powder, 0.8% glutamic acid and 1% vitamin E, mix and freeze-dry to obtain Lactobacillus rhamnosus JM039 powder. The content of Lactobacillus rhamnosus JM039 in the powder is 1.5×10 8 cfu / g.

[0026] (3) Preparation of Lactobacillus rhamnosus JY027 powder Inoculate Lactobacillus rhamnosus JY027 into MRS liquid culture medium at a 4% inoculation rate and activate at 37°C for 16 hours. Use an inoculation loop to take a small amount of bacterial liquid and make three-zone lines on MRS solid culture medium. Culture at 37°C for 48 hours, pick a single colony to the fermentation medium, and culture at 37°C for 16 hours to obtain the bacteria. Centrifuge the bacteria, add a freeze-drying protective solution containing 10% skim milk powder, 0.8% glutamic acid and 1% vitamin E, mix and freeze-dry to obtain Lactobacillus rhamnosus JY027 powder. The content of Lactobacillus rhamnosus JY027 in the powder is 3.0×10 8 cfu / g.

[0027] The preparation of modified montmorillonite is as follows: Add 100 mL of 1 mol / L NaCl solution to 10 g of montmorillonite, stir magnetically for 24 h, remove the supernatant by centrifugation, wash with deionized water, dry at 60 °C for 24 h, and crush to obtain Na-based montmorillonite; take 1 g of chitosan and dissolve it in 50 mL of 5% acetic acid, add 10 g of Na-based montmorillonite, stir for 20 h, remove the supernatant by centrifugation, wash with deionized water, dry for 24 h, and crush to obtain chitosan-modified montmorillonite.

[0028] Example 1

[0029] A method for preparing a Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea comprises the following steps: 1 part of inulin, 1 part of xylitol, 2 parts of lactulose, 0.2 parts of resistant dextrin, 6 parts of hawthorn extract, 4 parts of dandelion extract and 0.2 parts of modified montmorillonite are stirred and mixed evenly, sterilized at 120°C, and then 6 parts of Lactobacillus plantarum JY055 powder, 4 parts of Lactobacillus rhamnosus JM039 powder and 1 part of Lactobacillus rhamnosus JY027 powder are added and mixed evenly to obtain a Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea.

[0030] Example 2

[0031] A method for preparing a Lactobacillus rhamnosus composition for alleviating gastrointestinal diarrhea comprises the following steps: 2 parts of inulin, 3 parts of xylitol, 5 parts of lactulose, 0.6 parts of resistant dextrin, 10 parts of hawthorn extract, 7 parts of dandelion extract and 0.4 parts of modified montmorillonite are stirred and mixed evenly, sterilized at 120°C, and then 8 parts of Lactobacillus plantarum JY055 powder, 5 parts of Lactobacillus rhamnosus JM039 powder and 3 parts of Lactobacillus rhamnosus JY027 powder are added and mixed evenly to obtain a Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea.

[0032] Example 3

[0033] A method for preparing a Lactobacillus rhamnosus composition for alleviating gastrointestinal diarrhea comprises the following steps: 1.5 parts of inulin, 2 parts of xylitol, 4 parts of lactulose, 0.4 parts of resistant dextrin, 8 parts of hawthorn extract, 5 parts of dandelion extract and 0.3 parts of modified montmorillonite are stirred and mixed evenly, sterilized at 120°C, and then 7 parts of Lactobacillus plantarum JY055 powder, 4.5 parts of Lactobacillus rhamnosus JM039 powder and 2 parts of Lactobacillus rhamnosus JY027 powder are added and mixed evenly to obtain a Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea.

[0034] Comparative Example 1 A method for preparing a composition comprises the following steps: 1 part of inulin, 1 part of xylitol, 2 parts of lactulose, 0.2 parts of resistant dextrin, 6 parts of hawthorn extract, 4 parts of dandelion extract and 0.2 parts of modified montmorillonite are stirred and mixed evenly, sterilized at 120°C, and then 4 parts of Lactobacillus rhamnosus JM039 powder and 1 part of Lactobacillus rhamnosus JY027 powder are added and mixed evenly to obtain a composition.

[0035] Comparative Example 2 A method for preparing a composition comprises the following steps: 1 part of inulin, 1 part of xylitol, 2 parts of lactulose, 0.2 parts of resistant dextrin, 6 parts of hawthorn extract, 4 parts of dandelion extract and 0.2 parts of modified montmorillonite are stirred and mixed evenly, sterilized at 120°C, and then 6 parts of Lactobacillus plantarum JY055 powder and 1 part of Lactobacillus rhamnosus JY027 powder are added and mixed evenly to obtain a composition.

[0036] Comparative Example 3 A method for preparing a composition comprises the following steps: 1 part of inulin, 1 part of xylitol, 2 parts of lactulose, 0.2 parts of resistant dextrin, 6 parts of hawthorn extract, 4 parts of dandelion extract and 0.2 parts of modified montmorillonite are stirred and mixed evenly, sterilized at 120°C, and then 6 parts of Lactobacillus plantarum JY055 powder and 4 parts of Lactobacillus rhamnosus JM039 powder are added and mixed evenly to obtain a composition.

[0037] Comparative Example 4 A method for preparing a composition comprises the following steps: 1 part of inulin, 1 part of xylitol, 2 parts of lactulose, 0.2 parts of resistant dextrin, 6 parts of hawthorn extract and 4 parts of dandelion extract are stirred and mixed evenly, sterilized at 120°C, and then 6 parts of Lactobacillus plantarum JY055 powder, 4 parts of Lactobacillus rhamnosus JM039 powder and 1 part of Lactobacillus rhamnosus JY027 powder are added and mixed evenly to obtain a composition.

[0038] Comparative Example 5 A method for preparing a composition comprises the following steps: 1 part of inulin, 1 part of xylitol, 2 parts of lactulose, 0.2 parts of resistant dextrin, 4 parts of dandelion extract and 0.2 parts of modified montmorillonite are stirred and mixed evenly, sterilized at 120°C, and then 6 parts of Lactobacillus plantarum JY055 powder, 4 parts of Lactobacillus rhamnosus JM039 powder and 1 part of Lactobacillus rhamnosus JY027 powder are added and mixed evenly to obtain a composition.

[0039] Test methods and results Method for establishing mouse diarrhea model: BALB / c mice aged 6-8 weeks were selected and firstly fed adaptively for one week. Then, in addition to normal feed and drinking water, ETEC toxin (1 mg / kg body weight) was orally administered daily for 21 days. The model was successfully established when the diarrhea symptoms of mice lasted for at least 24 hours.

[0040] Experimental groups and dosage: 45 6-8 week old BALB / c mice with successful modeling were randomly divided into 9 groups, 5 mice in each group (diarrhea mice), and the compositions prepared in Examples 1-3 and Comparative Examples 1-5 were taken respectively; the positive control group (5 diarrhea mice) was taken with Daqing antidiarrhea oral liquid; the negative control group (5 healthy mice) was taken with the same volume of distilled water. The drugs were orally administered once in the morning and evening (200 mg / kg body weight) for 30 days. The sampling time was 1 day before taking the composition and 2 days after taking the composition.

[0041] (1) Effect of the composition on improving diarrhea symptoms in patients with diarrhea Daily defecation frequency: During the intervention of the composition, the number of daily defecation of each group of all test mice was counted every week, and the average number of daily defecation of each group was counted every week. The defecation frequency of mice within 4 weeks of the composition intervention is shown in Table 1. The obtained data were statistically processed and expressed as mean ± standard deviation (x ± s), and the significance of the difference was determined by t test. The P value was calculated by comparing the positive control group with the negative control group, and comparing each drug-treated group with the positive control group. (** indicates that P < 0.01 is an extremely significant difference, and * indicates that P < 0.05 is a significant difference).

[0042] Table 1 Changes in the frequency of bowel movements in patients during the intervention with the combination

[0043] As can be seen from Table 1, the average daily bowel movement frequency of the diarrheal mice was 35.9-39.7 times / day before the intervention of the composition, 32.6-32.8 times / day after 1 week of intervention with the composition of Examples 1-3 of the present invention, 27.3-29.5 times / day after 2 weeks of intervention with the composition, 21.0-25.9 times / day after 3 weeks of intervention with the composition, and 16.9-19.0 times / day after 4 weeks of intervention with the composition. The bowel movement frequency of the diarrheal mice in the embodiment group was basically restored to a normal level; the bowel movement frequency of the composition of Comparative Examples 1-5 was 32.0-34.3 times / day after 1 week of intervention with the composition, 29.0-30.4 times / day after 2 weeks of intervention with the composition, 26.0-28.9 times / day after 3 weeks of intervention with the composition, and 22.5-24.7 times / day after 4 weeks of intervention with the composition. The bowel movement frequency of the diarrheal mice in the comparative example group did not return to a normal level.

[0044] Fecal trait score: During the intervention of the composition, the fecal trait score of all diarrheal mice was statistically analyzed for each group every week, and the daily average fecal trait score of each group was plotted. The fecal trait scores of diarrheal mice within 4 weeks of the composition intervention were shown in Figure 2. Figure 1 .

[0045] Defecation 20 times or more per day, and abnormal stool characteristics, such as loose stools and watery stools. The stool characteristics are judged by the loose stool grade score. During the experiment, the stool shape of each group of mice was observed and the loose stool score was performed. Loose stool grade: As = normal stool 2 points, Bs = semi-solid stool 5 points, Cs = watery stool 8 points. The loose stool score of each group is the average of the loose stool scores of each breed of mice. The loose stool score of each mouse = (As x N1+ Bs x N2+ Cs x N3) / N, where As, Bs, Cs are the loose stool grade scores, N1, N2, N3 are the number of times the corresponding loose stool grade occurs, and N is the total number of bowel movements.

[0046] Depend on Figure 1 It can be seen that the average stool trait score of the diarrhea mice was 6.3~6.8 before the intervention of the composition, with obvious diarrhea symptoms; after taking the composition provided by the present invention for 1 week, the average stool trait score was 5.4~5.8, and there were still diarrhea symptoms, but the symptoms were alleviated; after taking it for 2 weeks, the average stool trait score was 4.7~4.9, which basically reached the normal level; the average stool trait score was 4.0~4.3 after taking it for 3 weeks, and the average stool trait score was 4.0~4.2 after taking it for 4 weeks, reaching the ideal stool shape. After taking the composition provided by the comparative example for 1 week, the average stool trait score was 6~6.5, and there were still diarrhea symptoms, but the symptoms were alleviated; after taking it for 2 weeks, the average stool trait score was 5.8~6.4, and there were still diarrhea symptoms; after taking it for 3 weeks, the average stool trait score was 5.7~6.1, and after taking it for 4 weeks, the average stool trait score was 5.2~6.0, and there was still diarrhea.

[0047] (2) Effects of the composition on intestinal flora Before and 2 h after the test, the feces of healthy mice were collected aseptically, and the fecal intestinal flora was detected using the 16SrRNA intestinal gene detection kit. The gene expression levels of Bacteroides, Prevotella and Staphylococcus aureus in the feces were counted, and the average value of each group was calculated. The results are shown in Table 2.

[0048] Table 2 Statistical table of the effects of the composition on intestinal flora

[0049] As shown in Table 2, the contents of Bacteroides and Prevotella in the intestinal tract of mice taking the composition of the present invention increased compared with before taking the composition, while the content of Staphylococcus aureus decreased compared with before taking the composition of the present invention, indicating that the composition of the present invention can regulate the intestinal flora and reduce the risk of diarrhea.

[0050] The above are only preferred embodiments of the present invention, and do not limit the patent scope of the present invention. For those skilled in the art, the present invention may have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the patent protection scope of the present invention.

Claims

1. A Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea, characterized in that: The composition consists of a probiotic mixture, a prebiotic mixture and a carrier, wherein the probiotic mixture consists of Lactobacillus plantarum JY055 powder, Lactobacillus rhamnosus JM039 powder and Lactobacillus rhamnosus JY027 powder, the prebiotic mixture comprises inulin, xylitol, lactulose, resistant dextrin, hawthorn extract and dandelion extract, and the carrier is modified montmorillonite.

2. The Lactobacillus rhamnosus composition for alleviating gastrointestinal diarrhea according to claim 1, characterized in that: The mass ratio of the probiotic mixture to the prebiotic mixture is (3-6):(4-8).

3. The Lactobacillus rhamnosus composition for alleviating gastrointestinal diarrhea according to claim 1, characterized in that: The viable bacterial count of the Lactobacillus plantarum JY055 powder is ≥1.0×10 9 CFU / g, the viable count of the Lactobacillus rhamnosus JM039 powder is ≥1.0×10 8 CFU / g, the viable count of the Lactobacillus rhamnosus JY027 powder is ≥2.0×10 8 CFU / g.

4. The Lactobacillus rhamnosus composition for alleviating gastrointestinal diarrhea according to claim 1, characterized in that: The mass ratio of Lactobacillus plantarum JY055 powder, Lactobacillus rhamnosus JM039 powder and Lactobacillus rhamnosus JY027 powder in the probiotic mixture is (6-8): (4-5): (1-3).

5. The Lactobacillus rhamnosus composition for alleviating gastrointestinal diarrhea according to claim 1, characterized in that: The preparation method of the modified montmorillonite comprises the following steps: NaCl solution is added to montmorillonite, stirred, centrifuged to remove the supernatant, washed with deionized water, dried, and crushed to obtain Na-based montmorillonite; chitosan is dissolved in acetic acid, added to the Na-based montmorillonite, stirred, centrifuged to remove the supernatant, washed with deionized water, dried, and crushed to obtain modified montmorillonite.

6. The Lactobacillus rhamnosus composition for alleviating gastrointestinal diarrhea according to claim 1, characterized in that: The mass ratios of inulin, xylitol, lactulose, resistant dextrin, hawthorn extract, dandelion extract and modified montmorillonite are (1-2): (1-3): (2-5): (0.2-0.6): (6-10): (4-7), (0.2-0.4).

7. A method for preparing a Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea according to any one of claims 1 to 6, characterized in that: The following steps are involved: Inulin, xylitol, lactulose, resistant dextrin, hawthorn extract, dandelion extract and modified montmorillonite are stirred and mixed evenly according to proportion, sterilized at 110-130° C., and then Lactobacillus plantarum JY055 powder, Lactobacillus rhamnosus JM039 powder and Lactobacillus rhamnosus JY027 powder are added and mixed evenly to obtain a Lactobacillus rhamnosus composition for relieving gastrointestinal diarrhea.

8. Use of the composition according to any one of claims 1 to 6 in the preparation of a drug for alleviating diarrhea.

Images